518044-32-1

Basic information

• Product Name: Hydroxy-PEG-5-t-butyl ester
• Synonyms: Hydroxy-PEG-5-t-butyl ester;PEG5-t-butly ester;Hydroxy-PEG4-t-butly ester;OH-PEG4-CH2CH2COOtBu
• CAS NO: 518044-32-1
• Molecular Formula: C₁₅H₃₀O₇
• Molecular Weight: 322.3945
• Mol File: 518044-32-1.mol

Chemical Properties

• Boiling Point: 406.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.04746 g/mL
• Refractive Index: n/D 1.4492
• Storage Temp.: 2-8°C
• Solubility: Soluble in Water, DCM
• PKA: 14.36±0.10(Predicted)
• CAS DataBase Reference: Hydroxy-PEG-5-t-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Hydroxy-PEG-5-t-butyl ester(518044-32-1)
• EPA Substance Registry System: Hydroxy-PEG-5-t-butyl ester(518044-32-1)

Safety Data

• Hazardous Substances Data: 518044-32-1(Hazardous Substances Data)

Usage

Uses

Used in Chemical Biology and Medicinal Chemistry:
Hydroxy-PEG-5-t-butyl ester is used as a building block for the synthesis of small molecules, conjugates of small molecules and/or biomolecules, or other tool compounds for chemical biology and medicinal chemistry that require ligation.
Used in Bioconjugation:
Hydroxy-PEG-5-t-butyl ester is used as a crosslinker for bioconjugation, allowing the attachment of various molecules to biomolecules such as antibodies or proteins.
Used in Drug Delivery Systems:
Hydroxy-PEG-5-t-butyl ester is used as a component in the development of drug delivery systems, such as antibody-drug conjugates or proteolysis-targeting chimeras (PROTAC molecules) for targeted protein degradation.
Used in Pharmaceutical Industry:
Hydroxy-PEG-5-t-butyl ester is used as a synthetic component in the production of pharmaceuticals, enhancing the solubility and bioavailability of drug molecules.
Used in Research and Development:
Hydroxy-PEG-5-t-butyl ester is used as a versatile reagent in research and development for the creation of novel bioconjugates and drug delivery systems, contributing to the advancement of medical treatments and therapies.

Upstream product

• 4792-15-8 Pentaethylene glycol 
• 1663-39-4 tert-Butyl acrylate 
• 112-60-7 Tetraethylene glycol 

Downstream Products

• 1427004-19-0 2,5-dioxopyrrolidin-1-yl 1-(4-{2-azatricyclo[10.4.0.0^4,9]hexadeca-1⁽¹²⁾,4⁽⁹⁾,5,7,13,15-hexane-10-yn-2-yl}-4-oxobutanamido)-3,6,9,12-tetraoxapentadecan-15-oate 
• 870487-48-2 tert-butyl 1-(methanesulfonyloxy)-3,6,9,12-tetraoxapentadecan-15-oate 
• 518044-41-2 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,6,9,12-tetraoxapentadecan-15-oic acid 
• 518044-36-5 tert-butyl 15-maleimido-4,7,10,13-tetraoxapentadecanoate 
• 663921-15-1 3-[2-(2-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}ethoxy)ethoxy]propanoic acid 
• 1415329-21-3 C₅₆H₉₄N₆O₁₂S 
• 581065-94-3 tert-butyl 3-[2-(2-{2-[2-(toluene-4-sulfonyloxy)-ethoxy]ethoxy}ethoxy)ethoxy]propionate 
• 1415329-30-4 C₅₂H₈₇N₇O₁₂S 

Relevant articles and documents

A new route for the synthesis of 1-amino-3,6,9,12-tetraoxapentadecan-15-oic acid

1-Amino-3,6,9,12-tetraoxapentadecan-15-oic acid 8 was synthesised from tetraethylene glycol through a 7 step sequence including esterification, mesylation, azide substitution with subsequent reduction followed by hydrolysis. The structure of product 8 was

PROTAC small molecular compound and application thereof

The invention discloses a compound with a general formula I, or a pharmaceutically acceptable salt, a stereoisomer, an ester, a prodrug, a solvate and a deuterated compound thereof, a composition containing the compound with the general formula I, and application of the compound with the general formula I or the pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate and deuteratedcompound thereof in preparation of medicines for treating diseases related to serine/threonine kinase family (MAP4Ks), preferably medicines for treating diseases related to hematopoietic stem cell kinase 1 (HPK1).

USES OF ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES

Described herein are anti-CD3 antibody folate bioconjugates and uses thereof in the treatment of diseases, conditions, and cancers.

ANTI-CD3 ANTIBODY FOLATE BIOCONJUGATES AND THEIR USES

Described herein are novel anti-CD3 Folate antibodies and uses thereof in the treatment of diseases or conditions that would benefit from such.

BIFUNCTIONAL SUBSTITUED PYRIMIDINES AS MODULATORS OF FAK PROTEOLYSE

The present disclosure relates to bifunctional compounds, which find utility as modulators of focal adhesion kinase (FAK) or protein tyrosine kinase 2 (PTK2). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS

Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/ infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Optimization of IEDDA bioorthogonal system: Efficient process to improve trans-cyclooctene/tetrazine interaction

The antibody pretargeting approach for radioimmunotherapy (RIT) using inverse electron demand Diels-Alder cycloaddition (IEDDA) constitutes an emerging theranostic approach for solid cancers. However, IEDDA pretargeting has not reached clinical trial. The major limitation of the IEDDA strategy depends largely on trans-cyclooctene (TCO) stability. Indeed, TCO may isomerize into the more stable but unreactive cis-cyclooctene (CCO), leading to a drastic decrease of IEDDA efficiency. We have thus developed both efficient and reproducible synthetic pathways and analytical follow up for (PEGylated) TCO derivatives, providing high TCO isomeric purity for antibody modification. We have set up an original process to limit the isomerization of TCO to CCO before the mAbs’ functionalization to allow high TCO/tetrazine cycloaddition.

Preparation method, raw material, product and application of photo-crosslinking hydrogel material

The invention provides a preparation method, a raw material, a product and an application of a photo-crosslinking hydrogel material. The preparation method comprises the steps of dissolving a component A, namely a photosensitive high polymer derivative, i

STEROIDS AND PROTEIN-CONJUGATES THEREOF

Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation

Enzymatic inhibition has proven to be a successful modality for the development of many small-molecule drugs. In recent years, small-molecule-induced protein degradation has emerged as an orthogonal therapeutic strategy that has the potential to expand the druggable target space. Focal adhesion kinase (Fak) is a key player in tumor invasion and metastasis, acting simultaneously as a kinase and a scaffold for several signaling proteins. While previous efforts to modulate Fak activity were limited to kinase inhibitors with low success in clinical studies, protein degradation offers a possibility to simultaneously block Fak's kinase signaling and scaffolding capabilities. Here, we report the development of a selective and potent Fak degrader, PROTAC-3, which outperforms a clinical candidate, defactinib, with respect to Fak activation as well as Fak-mediated cell migration and invasion. These results underline the potential that PROTACs offer in expanding the druggable space and controlling protein functions that are not easily addressed by traditional small-molecule therapeutics.